Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial

医学 乳腺癌 阶段(地层学) 化疗 内科学 彭布罗利珠单抗 肿瘤科 完全响应 新辅助治疗 癌症 免疫疗法 生物 古生物学
作者
Rita Nanda,MC Liu,Christina S. F. Yau,Rebecca Arielle Shatsky,Lajos Pusztai,Anne Marie Wallace,Amy Jo Chien,Andres Forero,Erin D. Ellis,Heather Han,Amy Sanders Clark,Kathy S. Albain,Judy Caroline Boughey,Nora T. Jaskowiak,ANTHONY D. ELIAS,Claudine J. Isaacs,Kathleen A. Kemmer,Teresa L. Helsten,Melanie Catherine Majure,Erica Michelle Stringer-Reasor
出处
期刊:JAMA Oncology [American Medical Association]
卷期号:6 (5): 676-676 被引量:788
标识
DOI:10.1001/jamaoncol.2019.6650
摘要

Importance: Approximately 25% of patients with early-stage breast cancer who receive (neo)adjuvant chemotherapy experience a recurrence within 5 years. Improvements in therapy are greatly needed. Objective: To determine if pembrolizumab plus neoadjuvant chemotherapy (NACT) in early-stage breast cancer is likely to be successful in a 300-patient, confirmatory randomized phase 3 neoadjuvant clinical trial. Design, Setting, and Participants: The I-SPY2 study is an ongoing open-label, multicenter, adaptively randomized phase 2 platform trial for high-risk, stage II/III breast cancer, evaluating multiple investigational arms in parallel. Standard NACT serves as the common control arm; investigational agent(s) are added to this backbone. Patients with ERBB2 (formerly HER2)-negative breast cancer were eligible for randomization to pembrolizumab between November 2015 and November 2016. Interventions: Participants were randomized to receive taxane- and anthracycline-based NACT with or without pembrolizumab, followed by definitive surgery. Main Outcomes and Measures: The primary end point was pathologic complete response (pCR). Secondary end points were residual cancer burden (RCB) and 3-year event-free and distant recurrence-free survival. Investigational arms graduated when demonstrating an 85% predictive probability of success in a hypothetical confirmatory phase 3 trial. Results: Of the 250 women included in the final analysis, 181 were randomized to the standard NACT control group (median [range] age, 47 [24.77] years). Sixty-nine women (median [range] age, 50 [27-71] years) were randomized to 4 cycles of pembrolizumab in combination with weekly paclitaxel followed by AC; 40 hormone receptor (HR)-positive and 29 triple-negative. Pembrolizumab graduated in all 3 biomarker signatures studied. Final estimated pCR rates, evaluated in March 2017, were 44% vs 17%, 30% vs 13%, and 60% vs 22% for pembrolizumab vs control in the ERBB2-negative, HR-positive/ERBB2-negative, and triple-negative cohorts, respectively. Pembrolizumab shifted the RCB distribution to a lower disease burden for each cohort evaluated. Adverse events included immune-related endocrinopathies, notably thyroid abnormalities (13.0%) and adrenal insufficiency (8.7%). Achieving a pCR appeared predictive of long-term outcome, where patients with pCR following pembrolizumab plus chemotherapy had high event-free survival rates (93% at 3 years with 2.8 years' median follow-up). Conclusions and Relevance: When added to standard neoadjuvant chemotherapy, pembrolizumab more than doubled the estimated pCR rates for both HR-positive/ERBB2-negative and triple-negative breast cancer, indicating that checkpoint blockade in women with early-stage, high-risk, ERBB2-negative breast cancer is highly likely to succeed in a phase 3 trial. Pembrolizumab was the first of 10 agents to graduate in the HR-positive/ERBB2-negative signature. Trial Registration: ClinicalTrials.gov Identifier: NCT01042379.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
小蘑菇的应助被VitoLi采纳,获得10
刚刚
科研通AI6.4的应助被152455采纳,获得10
刚刚
科研通AI6.2的应助被和平发展采纳,获得10
刚刚
着急的草莓的应助被xin采纳,获得10
1秒前
慕青的应助被Nocte采纳,获得10
2秒前
外向的烟完成签到,获得积分10
2秒前
欣喜巧曼发布了新的文献求助10
2秒前
wp0715发布了新的文献求助10
3秒前
3秒前
3秒前
3秒前
wanci的应助被十七采纳,获得100
4秒前
5秒前
5秒前
九上草完成签到,获得积分10
6秒前
勤奋一一发布了新的文献求助10
6秒前
赘婿的应助被岛岛主采纳,获得10
6秒前
科研通AI6.2的应助被缓慢念波采纳,获得10
7秒前
科研通AI6.2的应助被淳于黎昕采纳,获得10
7秒前
wp0715完成签到,获得积分10
8秒前
负责以山发布了新的文献求助10
9秒前
OaO发布了新的文献求助10
9秒前
任性的苞络完成签到 ,获得积分10
9秒前
灰鸽子完成签到,获得积分10
10秒前
10秒前
玫瑰555发布了新的文献求助10
10秒前
雪山飞龙发布了新的文献求助100
11秒前
louiselin发布了新的文献求助10
11秒前
12秒前
xin完成签到,获得积分10
14秒前
14秒前
15秒前
12345676543发布了新的文献求助10
15秒前
yzb发布了新的文献求助10
16秒前
16秒前
16秒前
unique完成签到 ,获得积分10
17秒前
专注香芦完成签到 ,获得积分10
17秒前
岛岛主完成签到,获得积分10
18秒前
18秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Markov Decision Processes and Reinforcement Learning 700
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8171069
求助须知:如何正确求助?哪些是违规求助? 9563791
关于积分的说明 21772202
捐赠科研通 7762628
什么是DOI,文献DOI怎么找? 3430786
关于科研通互助平台的介绍 2554696
邀请新用户注册赠送积分活动 2475672